Ophthalmic Surg Lasers Imaging Retina. 2023 Feb;54(2):89-96. doi: 10.3928/23258160-20221216-02. Epub 2023 Feb 1.
To report the 3-year outcomes for endolaserless vitrectomy with intravitreal aflibercept injection (IAI) monotherapy for proliferative diabetic retinopathy (PDR)-related vitreous hemorrhage (VH).
Eyes underwent endolaserless vitrectomy and received one preoperative and intraoperative IAI followed by randomization to a q8week or q16week IAI group. Additional IAI was administered as needed.
31/40 eyes were randomized (14 q8week eyes, 17 q16week eyes). Through 152 weeks, q8week and q16week eyes received 18.6 and 12.1 IAI, respectively. Q8week eyes observed a 34 letter visual acuity (VA) increase ( = 0.003) compared to a 27 letter increase in the q16week group ( = 0.013).
Endolaserless vitrectomy with aflibercept monotherapy for PDR-related VH provides significant long-term visual gains. Frequent IAI is required for fewer proliferative consequences. .
报告增生型糖尿病视网膜病变（PDR）相关玻璃体出血（VH）患者行无内界膜激光玻璃体切除术联合玻璃体内注射阿柏西普（IAI）单药治疗的 3 年结局。
患者行无内界膜激光玻璃体切除术，于术前和术中接受单次 IAI，并随机分为 q8 周 IAI 组或 q16 周 IAI 组，根据需要追加 IAI。
40 只眼中有 31 只（14 只 q8 周眼，17 只 q16 周眼）被随机分配。在 152 周时，q8 周眼和 q16 周眼分别接受了 18.6 和 12.1 次 IAI。q8 周眼的视力（VA）提高了 34 个字母（=0.003），而 q16 周眼的 VA 提高了 27 个字母（=0.013）。
无内界膜激光玻璃体切除术联合阿柏西普单药治疗 PDR 相关 VH 可带来显著的长期视力获益，频繁应用 IAI 可减少增生性并发症。
